Optellum

Optellum is a private, commercial-stage diagnostics company at the forefront of applying artificial intelligence to improve lung cancer outcomes. Its FDA-cleared and CE-marked Virtual Nodule Clinic platform provides a clinical decision support tool that analyzes CT scans to help physicians identify and manage potentially cancerous lung nodules earlier and more accurately. By targeting the critical gap in early detection, Optellum aims to standardize care, reduce unnecessary invasive procedures, and ultimately increase survival rates. The company is positioned in a high-growth segment of the digital health and AI diagnostics market, backed by venture capital and strategic partnerships.

AI-powered imaging analytics platform that uses deep learning on CT scans to compute a Lung Cancer Prediction (LCP) score for pulmonary nodule malignancy risk assessment.

Optellum competes in the AI-powered medical imaging diagnostics space, facing competition from large medical imaging OEMs (e.g., GE HealthCare, Siemens), pure-play AI software companies (e.g., Aidoc, Zebra Medical), and other specialized lung cancer AI firms (e.g., Riverain Technologies, behold.ai). Its differentiation lies in its specific FDA clearance for lung cancer prediction, its clinically validated LCP score, and its focus on seamless clinical workflow integration.